The painkiller aspirin will be evaluated as a possible treatment for Covid-19 in one of Britain’s biggest trials, which will assess whether it might reduce the risk of blood clots in people with the disease.
Shares in Solid Biosciences Inc. plunged 71 percent after a clinical trial testing the company’s gene therapy for a muscle-wasting disorder was halted for the second time in less than two years.
The CEO of Platelet BioGenesis sees a future in the development of an on-demand platelet product made from stem cells.
An advisory committee of the EMA recommended conditionally approving a drug from Akcea Therapeutics and Ionis Pharmaceuticals that aims to treat a rare genetic disease.
The U.S. Food and Drug Administration expanded the use of Novartis AG’s low platelets drug Promacta to treat patients with a rare, genetic blood disorder.
The U.S. FDA declined to approve a drug from Akcea Therapeutics and Ionis Pharmaceuticals that aims to treat a genetic disease that causes fat accumulation in the blood.